Several studies have been conducted on CD38‐targeted nanoparticles loaded with chemotherapeutic agents for MM treatment26, 27, 28, 29; however, no studies of engineered CD38‐targeted EVs within MNs have been reported. The gene discussed is CD38; the disease is Miyoshi myopathy.